Cytotherapy

• 

  Publication Venue For

  • Cord blood derived cell therapy product, DUOC-01, accelerates remyelination in a murine model of cuprizone induced demyelination.  17:S55-S55. 2015
  • Human cord blood derived CD14 cell therapy provides neuroprotection in aquired brain injury.  17:S57-S57. 2015
  • Neural engraftment of a cord blood-derived cell product following intrathecal transplantation.  17:S56-S56. 2015
  • The use of hydroxyethyl starch (HES) as a substitute for dextran 40 in the thaw and washing of HPC, apheresis products.  17:S60-S60. 2015
  • DUOC-01, A CANDIDATE CELL THERAPY PRODUCT DERIVED FROM BANKED CORD BLOOD, ACCELERATES BRAIN REMYELINATION IN NSG MICE FOLLOWING CUPRIZONE FEEDING.  16:S61-S62. 2014
  • Neuronal and glial cell composition in a mouse brain slice culture model is useful in developing human cord blood derived cellular therapies for neonatal hypoxic-ischemic brain injury.  16:S61-S61. 2014
  • PROTECTION OF BRAIN CELLS IN ORGANOTYPIC SLICE CULTURES EXPOSED TO OXYGEN AND GLUCOSE DEPRIVATION IS SPECIFICALLY MEDIATED BY CORD BLOOD CD14+CELLS.  16:S61-S61. 2014
  • Preclinical characterization of DUOC-01, a candidate cell therapy product derived from human banked umbilical cord blood intended for use in treatment of demyelinating diseases.  16:S16-S17. 2014
  • Tissue distribution of a cord blood-derived cell product following intrathecal transplantation.  16:S63-S63. 2014
  • Immune reconstitution after unrelated cord blood transplantation..  9:111-122. 2007
  • Isolation of early hematopoietic cells, including megakaryocyte progenitors, in the ALDH-bright cell population of cryopreserved, banked UC blood..  9:569-576. 2007
  • Modification of a commercial cell sorter to support efficient and reliable preparation of ALDH-bright cells for clinical use..  9:562-568. 2007
  • AML-loaded DC generate Th1-type cellular immune responses in vitro..  8:95-104. 2006
  • Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma.  8:580-588. 2006
  • Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting..  7:126-133. 2005
  • A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation..  6:1-6. 2004
  • Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal..  6:328-336. 2004
  • Adipose-derived adult stem cells: isolation, characterization, and differentiation potential..  5:362-369. 2003
  • Human umbilical cord blood derived cell therapy product, DUOC-01, ameliorates experimental autoimmune encephalomyelitis, a mouse model for multiple sclerosis 2019
  • Meeting the demands of msc production for clinical studies 2019
  • MANUFACTURING OF ALLOGENEIC HUMAN CORD TISSUE MESENCHYMAL STROMAL CELLS: INITIAL RESULTS OF A PHASE I CLINICAL TRIAL IN CHILDREN WITH AUTISM SPECTRUM DISORDER 2018
  • TARGETING NEUROINFLAMMATION WITH HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS 2018
  • TOWARDS A MECHANISM-BASED POTENCY ASSAY FOR CORD BLOOD UNITS IN TREATMENT OF HYPOXIC-ISCHEMIC BRAIN DAMAGE 2018
  • CHARACTERIZATION OF MSC DERIVED FROM UMBILICAL CORD TISSUES 2017
  • UMBILICAL CORD TISSUE DERIVED MESENCHYMAL STROMAL CELLS INHIBIT LYSOPHOSPHATIDYLCHOLINE MEDIATED ACTIVATION OF MICROGLIA IN ORGANOTYPIC CEREBELLAR CULTURES 2017
  • Aldehyde dehydrogenase, but not viability of CD34 cells, predicts potency and engraftment after cord blood transplantation 2015
  • Experience in a public cord blood bank using a segment-based aldehyde dehydrogenase assay as a biomarker for umbilical cord blood potency 2014